Research programme: antisense oligonucleotide MDM2 - Idera Pharmaceuticals

Drug Profile

Research programme: antisense oligonucleotide MDM2 - Idera Pharmaceuticals

Alternative Names: GEM 240; HDMAS5; Research programme: anti-MDM2 antisense oligonucleotides

Latest Information Update: 20 Dec 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Idera Pharmaceuticals; Johns Hopkins University; University of Alabama
  • Developer Genzyme Corporation; Idera Pharmaceuticals; University of Alabama
  • Class Antineoplastics; Nucleotides
  • Mechanism of Action Apoptosis stimulants; Proto-oncogene protein c mdm2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 31 Mar 2006 Discontinued - Preclinical for Cancer in USA (unspecified route)
  • 13 Sep 2005 Hybridon is now called Idera Pharmaceuticals
  • 05 Mar 2004 Preclinical data from a media release have been added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top